Perioperative administration of nivolumab and chemotherapy is superior to chemotherapy alone in prolonging event-free survival (EFS) in adult patients with resectable stage II/IIIb disease. Non-small cell...
Thirty- and 90-day survival were better among patients treated through surgical resection for their non–small cell lung cancer (NSCLC) in Medicaid-expansion states vs nonexpansion states, according...
Lyudmila A. Bazhenova, MD, medical oncologist, professor, medicine, the University of California San Diego (UCSD) Moores Cancer Center, discusses factors to consider when navigating the use of...
Biagio Ricciuti, MD, thoracic medical oncologist, staff scientist II, Department of Medicine, Dana-Farber Cancer Institute, discusses the association between PD-L1 expression levels and long-term survival with anti–PD-L1...
The proportion of certain blood immune cell types, predominately T cells and neutrophils, was linked with response to immune checkpoint inhibitors (ICIs) in patients with non–small...
Machine learning–aided prediction models are capable of learning the relationship between clinical features and later development of brain metastases (BM) in patients with non-small cell lung...
Recent Comments